Coastal Bridge Advisors, LLC
Position in HALO — Halozyme Therapeutics, Inc.
CIK 1665976
WESTPORT, CT
Position in HALO
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$937,135
-$49,213 QoQ
Shares Held
14,500
-1.1% QoQ
Ownership
0.012%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2023
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Coastal Bridge Advisors, LLC holds $9,671,803 across 13 Biotechnology names. HALO ranks #5 (9.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INCY |
Incyte Corp
|
22,175 | $2,087,111 | |
| 2 | DNA |
Ginkgo Bioworks Holdings, Inc.
|
276,817 | $1,696,888 | |
| 3 | PRAX |
Praxis Precision Medicines, Inc.
|
3,906 | $1,258,474 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,521 | $1,175,185 | |
| 5 | HALO |
Halozyme Therapeutics, Inc.
This page
|
14,500 | $937,135 | |
| 6 | URGN |
UroGen Pharma Ltd.
|
37,000 | $665,260 | |
| 7 | CNTA |
Centessa Pharmaceuticals plc
|
13,102 | $520,411 | |
| 8 | SPRY |
ARS Pharmaceuticals, Inc.
|
55,730 | $447,511 |
All Filings in HALO
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $937,135 | 14,500 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $986,348 | 14,656 | Shares | Sole | 2026-02-18 | |
| 2025-06-30 | $246,366 | 4,736 | Shares | Sole | 2025-08-14 | |
| 2024-03-31 | $406,800 | 10,000 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $295,680 | 8,000 | Shares | Sole | 2024-02-15 | |
| 2023-09-30 | $229,200 | 6,000 | Shares | Sole | 2023-11-14 | |
| 2023-06-30 | $216,420 | 6,000 | Shares | Sole | 2023-08-17 | |
| No filing history on record for this holder in this stock. | ||||||